NYLIM
VNDA icon

New York Life Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

New York Life Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,059
Closed -$215K – 1533
2023
Q4 		$215K Sell
51,059
-1,377
-3% -$5.56K ﹤0.01% 1286
2023
Q3 		$227K Sell
52,436
-8,261
-14% -$45.9K ﹤0.01% 1257
2023
Q2 		$400K Sell
60,697
-7,968
-12% -$51.1K ﹤0.01% 1007
2023
Q1 		$466K Buy
+68,665
New +$483K 0.01% 1103

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's VNDA Position: Q1 2024 in Review

New York Life Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 51,059 shares — an estimated $215K sold.

New York Life Investment Management first reported a position in VNDA in Q1 2023 and held it in 4 quarters. The position peaked at $466K in Q1 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • New York Life Investment Management reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 51,059 Vanda Pharmaceuticals shares in Q1 2024, an estimated $215K.
  • New York Life Investment Management first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • New York Life Investment Management's Vanda Pharmaceuticals position peaked at $466K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.